Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Perioperative Strategies in NSCLC: Future Directions and Challenges
In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.
Advancing the Field of Valve Interventions for Mitral and Tricuspid Regurgitation
While previous trials have led to questions surrounding the potential benefits of valve interventions in mitral or tricuspid regurgitation, a pair of trials presented recently demonstrate their potential, Javed Butler, MD, MPH, MBA, president of the Baylor Scott and White Research Institute, said.
Daratumumab Quadruplets Show Durable Outcomes in Transplant-Eligible Multiple Myeloma
Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, respectively.
FDA Approves Bimekizumab for Psoriatic Arthritis, Nonradiographic AxSpA, Ankylosing Spondylitis
Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and moderate to severe plaque psoriasis.
Positive KEYNOTE-522 Overall Survival Results in TNBC
The first overall survival analysis of the KEYNOTE-522 trial showed positive outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy vs neoadjuvant chemotherapy alone in high-risk early-stage triple-negative breast cancer (TNBC).
Dr Nicolas Girard on LUMINOSITY: Teliso-V Improves PROs in NSCLC
Nicolas Girard, MD, head of the Curie-Montsouris Thorax Institute, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial of telisotuzumab vedotin (Teliso-V) in non–small cell lung cancer (NSCLC).
POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC
Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM-303/InterAACT2 trial of retifanlimab plus chemotherapy for squamous cell carcinoma of the anal canal (SCAC).
Dr Jonathan Riess on the Potential of IO102-IO103, the Cancer Vaccine Landscape
Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced squamous cell carcinoma of the head and neck.
Fianlimab Plus Cemiplimab Shows Deep, Durable Responses in Melanoma: Dr Meredith McKean
Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and cemiplimab, Meredith McKean, MD, MPH, director of melanoma and skin cancer research for Sarah Cannon Research Institute, explained.
Dr Dax Kurbegov on Gaps Between Payers, Health Systems, and Providers in Oncology
Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.
Novel Imaging Algorithm Shows Promise in DMD Evaluation
Measurements on a standard phantom and a clinical data set of patients with Duchenne muscular dystrophy (DMD) were used to validate a novel robust reference frequency method approach, which outperformed typical imaging strategies.
Dr Ticiana Leal on Recent Advancements in Perioperative NSCLC Care
Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.
Neil Goldfarb Previews the 2024 GPBCH Annual Wellness Summit
Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the variety of themes and sessions at the upcoming GPBCH Annual Wellness Summit taking place September 10, 2024.